openPR Logo
Press release

Newly Approved Therapeutic Agents to Fuel Global Pulmonary Arterial Hypertension (PAH) Market’s Rise to US$5.19 Bn by 2020

11-22-2017 08:44 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Newly Approved Therapeutic Agents to Fuel Global Pulmonary

Transparency Market Research (TMR), a market intelligence and research firm, has published a market study on the global pulmonary arterial hypertension (PAH) market, estimating the total value of this worldwide market to be US$5.19 bn by 2020. The market was valued at US$4.04 bn in 2013 and is likely to expand at an impressive CAGR of 17.90% during the period from 2014 to 2020.The research report, titled “Pulmonary Arterial Hypertension (PAH) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, states that initiatives by several governments promoting the research and development of orphan drugs has been fueling the global market for PAH of late. Analysts project the recently approved therapeutic agents to stimulate the global PAH market significantly over the forecast period.

Read Report Overview @ https://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html

According to the market report, the global PAH market has been evaluated on the basis of drug classes and regional distribution. Prostacyclin, prostacyclin analogs, PDE-5 inhibitors, ERAs, and sGC stimulators are the key drugs available in the global market to treat PAH. ERAs led the global market in 2013, accounting for a market share of 55.8% in terms of revenue.

Analysts, however, have predicted that the market for prostacyclin and prostacyclin analogs will surpass the ERAs market by the end of the forecast period. The launch of the recently approved Orenitram is likely to propel this market segment during the forecast period. The approval for Uptravi, which is slated in Q1 of 2016, is also anticipated to add to the market segment’s growth prospects, notes the research study.North America, Europe, Asia Pacific, and the Rest of the World are the key regional markets for pulmonary arterial hypertension across the world. Among these, the PAH market in North America led the global market with a share of 44.6% in 2013 and was closely followed by the Europe PAH market.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

Over the forecast period, both these regional markets are expected to exhibit remarkable growth, owing to the availability of newly-approved PAH drugs as well as products waiting to gain approval in these markets.The Asia Pacific market for PAH is also projected to show significant development in the next few years. India, China, Japan, New Zealand, and Australia are likely to present opportunity-rich markets for enterprises operating in the global PAH market. On the other hand, the Rest in the World PAH market is facing severe challenges, owing to the low awareness level pertaining to the detection and treatment of pulmonary arterial hypertension, states the market study.

The major players operating in the global market for pulmonary arterial hypertension are Actelion Pharmaceuticals Ltd., Gilead Sciences Inc., Bayer HealthCare, GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, and United Therapeutics Corp., states the research report.

Buy Full Pulmonary Arterial Hypertension (PAH) Market Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1181<ype=S

About TMR

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Newly Approved Therapeutic Agents to Fuel Global Pulmonary Arterial Hypertension (PAH) Market’s Rise to US$5.19 Bn by 2020 here

News-ID: 827657 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for PAH

Development: Pulmonary Arterial Hypertension (PAH) Market Growth Analysis
The global pulmonary arterial hypertension (pah) market is estimated to surpass $9,670.2 million by 2027, exhibiting a CAGR of 5.8% from 2020 to 2027. The report provides all-inclusive analysis of global pulmonary arterial hypertension (pah) market with comprehensive study of the various facets of the market including market dynamics, major segments and regions, top leading players, and competitive landscape. Research Methodology Research Dive offers its clients extensive research and analysis gleaned from wide
Pulmonary Arterial Hypertension (PAH) Market Research and Clinical Analysis 2020
Global Pulmonary Arterial Hypertension (PAH) Market research report published by market insight reports explores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market, and divides the Market into several parameters. This Pulmonary Arterial Hypertension (PAH) Market research report identifies the competitive landscape of industries to understand the competition at International level.
Pulmonary Arterial Hypertension (PAH) Medicine Market (2020-2027) Report Offers …
The research study includes the latest updates about the COVID-19 impact on the Pulmonary Arterial Hypertension (PAH) Medicine sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy. The market research report on the global Pulmonary Arterial Hypertension (PAH) Medicine market provides an extensive and
Pulmonary Arterial Hypertension (PAH) - Market Outlook and Competitive Landscape …
Report Overview  The report provides a comprehensive view of disease events, types, severity, progression, symptoms, risk factors, pathogenesis and treatment guidelines at country level  Comprehensive insight on patient segmentation has been provided into the epidemiology of the Pulmonary Arterial Hypertension (PAH) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China  Drug utilization and analysis on the current
Global Pulmonary Arterial Hypertension (PAH) Market| MarketResearchReports.biz
Latest industry research report on: Global Pulmonary Arterial Hypertension (PAH) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V
Pulmonary Arterial Hypertension (PAH) Market by Key Players 
Global Pulmonary Arterial Hypertension (PAH) Market: Snapshot Pulmonary arterial hypertension (PAH) is a very rare type of progressive disorder related to high blood pressure. However, the rate of incidence of this disorder is gradually gaining traction. Various sources, including WHO and CDC, suggest that the global prevalence of PAH is anticipated to be between 100,000 and 200,000, narrowing down to about 15-50 cases per million heads. There is no permanent cure